Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6084714 | 0.98 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL11711177 | 0.90 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL8089093 | 0.84 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL5929756 | 0.84 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL242405 | 0.80 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL11791126 | 0.78 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL13163277 | 0.77 | LMNA (0.49) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL13993574 | 0.76 | EGFR (0.41) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL13163272 | 0.75 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2HPGDLMNAHTT | |
| SCHEMBL14221464 | 0.75 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HPGDLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389721-B2 | Solubilized topoisomerase poisons | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012015875-A1 | METHODS FOR TREATING HEMATOLOGICAL MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015901-A1 | METHODS FOR TREATING GASTRIC AND PANCREATIC MALIGNANCIES | GENZYME CORPORATION (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120004235-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-06-09 | — | — | US | disclosed |
| EP-2286812-A1 | Solubilized topoisomerase poisons | Rutgers, The State University (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7781587-B2 | antitumor; breast cancer; 8,9-Dimethoxy-2,3-methylenedioxy-5-[2-(N,N-dimethylamino)ethyl]-5H-dibenzo[c,h]1,6-naphthyridin-6-one | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-24 | — | — | US | disclosed |
| WO-2010088544-A1 | METHODS TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-2196205-A1 | Topoisomerase poisons | Rutgers, The State University (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-1465625-B1 | SOLUBILIZED TOPOISOMERASE POISONS | UNIV RUTGERS (US) | 2010-02-03 | — | — | EP | disclosed |
| EP-1465625-A2 | SOLUBILIZED TOPOISOMERASE POISONS | Rutgers, The State University (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1453812-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003041653-A2 | CYTOTOXIC AGENTS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003041660-A2 | SOLUBILIZED TOPOISOMERASE POISONS | RUTGERS, THE STATE UNIVERSITY (US) | 2003-05-22 | — | — | WO | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| US-5668162-A | Isothiazolones lower plasma levels of lipoprotein(a) | WARNER-LAMBERT COMPANY | 1997-09-16 | — | — | US | disclosed |
| US-4439436-A | BACTERICIDES | STERLING DRUG INC. (US) | 1984-03-27 | — | — | US | disclosed |
| US-3936461-A | Substituted 4-benzylquinolines | WARNER-LAMBERT COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
| US-3931192-A | Process for piperidine intermediates for quinine, quinidine and analogs thereof | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
| US-3931193-A | ANTIMALARIA, ANTIARRHYTHMIA INTERMEDIATES | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004235-A1 | METHODS TO TREAT CANCER | TP53, CCNY, ABCB1 | ALDH1A1 115/4885SMN1; SMN2 2209/4885HPGD 918/4885 |
| US-20110136812-A1 | SOLUBILIZED TOPOISOMERASE POISONS | TOP1, TOP2A, TOP2B | ALDH1A1 3459/4885SMN1; SMN2 1565/4885HPGD 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.